

PHS 398/2590 Other Support  
Kenneth Kopecky, Ph.D.

ACTIVE

<b>5 U10 CA38926 (John Crowley)</b>	01/01/2010 – 12/31/2015	3.12 cal mo
National Institutes of Health/National Cancer Institute	\$3,983,675	
Southwest Oncology Group Statistical Center		

The Southwest Oncology Group is a national consortium of institutions and investigators organized to improve survival of cancer patients through clinical research. The Statistical Center staff assist with study protocols, manages and edit study data, generate semiannual reports of findings, and conduct workshops on data management activities. They also research statistical aspects of Group studies and analyze and publish study results. Several programs previously funded via the Group Operations Office/Cancer Therapy and Research Center are included here: Cooperative Group Outreach Program (CGOP), Pathology Central Office, Urologic Cancer Outreach Program (UCOP), CTEP Minorities Program, High Priority Clinical Trials and Leukemia Biology.

<b>R01 CA114563 (Meshinchi)</b>	08/01/2005 – 07/31/2011	0.24 cal mo
National Cancer Institute	\$229,479	

Biology and Prognostic Implications of FLT3 Mutations in Acute Myelogenous Leukemia (AML)

This study will evaluate the prognostic significance of mutations of the FLT3 gene, mutations of RTK/Ras signal transduction pathway, as well as the FLT3 transcriptome levels in multi-institutional pediatric and adult AML trials.

<b>R01 CA118914-01A2 (Davis)</b>	09/26/2007 – 07/31/2012	1.20 cal mo
National Institutes of Health/National Cancer Institute	\$954,040	
Breast Cancer Risk and Molecular Change after Chernobyl		

This study will investigate whether individual radiation dose to the breast from the Chernobyl accident is associated with breast cancer risk, and to evaluate the relationship of breast cancer phenotype and genotype to radiation dose by comparing rates of inactivating genetic or epigenetic changes in 14 selected DNA repair genes to radiation dose.

<b>HHSN 268200900008C (DeRoos)</b>	01/05/2009 – 01/14/2011	0.60 cal mo
National Heart, Lung, and Blood Institute (NHLBI)	\$363,722	
Markers of B-Cell Stimulation as Potential Predictors of Non-Hodgkin Lymphoma		

The project goal is to design and execute a case-control study of non-Hodgkin lymphoma (NHL) nested within the Women's Health Initiative Observational Study cohort to test whether biologic markers measured in serum/plasma/DNA that are indicative of a B-cell stimulatory host environment are predictive of B-cell NHL incidence. Markers to be measured among 500 cases and 500 pair-matched controls include cytokines (e.g., IL6, IL10, TNF $\alpha$ ), cytokine-like molecules (sCD23), soluble cytokine receptors (sCD27, sCD30) and other molecules involved in B-cell response (sCD44, CXCL13), as well as EBV DNA load and antibodies to key EBV antigens (VCA, EBNA1, and EA-D).

<b>Cancer Research And Biostatistics (Kopecky)</b>	04/01/2010 – 03/31/2011	1.20 cal mo
Development of SWOG Specimen Tracking System	\$21,650	

Dr. Kopecky will provide oversight and leadership for the SpecTrack software and integration with the University of Colorado systems and the NCI. He will lead the effort to operationalize the reporting guidelines developed by the Group Banking Committee with the Specimen Tracking system. A priority is to evaluate design for compatibility with the NCI's caBIG database.

<b>R01 TE 5047 (Oehler)</b>	07/01/2009 – 06/30/2014	0.24 cal mo
NIH/NCI	\$207,500	
Integrating Diagnostics with Therapeutic Strategies in Chronic Myeloid Leukemia		
1. Identify and validate diagnostic genomic predictors of early CML progression and therapy resistance.		
2. Optimize and test sensitive strategies to detect resistance in patients on TKI therapy.		
3. Examine the role of select candidates in disease progression and therapy resistance.		
<b>R21 TE 5010 (Stirewalt)</b>	12/01/2009 – 11/30/2011	0.60 cal mo
NIH/NCI	\$130,755	
An Examination of IRF8 as a Biomarker of Aging, Malignant Transformation, and Prognosis		
Research that decreased IRF8 expression in aging HPC/HSCs causes myeloid skewing in older adults and the expansion of pre-malignant clones that have the potential to transform into overt myeloid malignancies with additional genetic hit. Dr. Kopecky will collaborate in the design, conduct, analysis and reporting of studies in support of these aims.		
<b>R01 ES0173030 (Wang)</b>	07/01/2010 – 05/30/2013	1.20 cal mo.
NIH/ES	\$190,233	
Functional Methods for Radiation Exposure and Biomarker Data		
The overall goals of this research are to investigate innovative methods for estimating dose-response relationships when exposure is measured with error and biomarker data correlated with exposure are available.		
<b>SWOG CTI S0325 (Kopecky)</b>	09/01/2009 – 12/31/2010	1.20 cal mo.
SWOG-CTI (Bristol Myers Squibb)	\$35,557	
S0325 "A Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses, or Dasatinib for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase"		
Develop, in collaboration with BMS and CRAB personnel, the plans for each of three transfers of data for the selected patients on study S0325: (1) a test data set of registration, eligibility and adverse event data, for the Company to use in developing programs for its analysis of the data; (2) a complete set of data regarding registration, eligibility and adverse event data; and (3) a complete data set including registration, eligibility and adverse event data, along with treatment outcomes (response, survival, relapse-free survival).		
<b>Institutional Support</b>	Ongoing	2.40 cal mos
Fred Hutchinson Cancer Research Center		

**PENDING**

Vanderbilt University Medical Center (John D Boice, Jr, PI)	04/01/10 – 03/31/15	1.20 cal mo
NIH	\$128,326	
Cancer Mortality among Military Participants at US Nuclear Weapons Tests		

A new mortality follow-up and comprehensive dose reconstruction to assess the risk of cancer among 120,000 United States military personnel who participated in any of seven aboveground atmospheric weapons tests at the Nevada Test Site (NTS) and the Pacific Proving Grounds between 1946 and 1958, is proposed in conjunction with an NIH R01 grant application to be submitted by Vanderbilt University Medical Center.

OVERLAP

There is no scientific or budgetary overlap in the grants and projects listed above. As of June 1, 2010, CA114762 will be complete, making 1.20 calendar months available, which is the amount of effort listed for Dr. Kopecky in the pending application "Cancer Mortality among Military Participants at US Nuclear Weapons Tests".